Cambridge, MA, Rotterdam, NL, Suzhou, CN - October 10, 2022

Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, announced today that it has entered into an agreement with CSPC NBP Pharmaceuticals Co., Ltd. (NBP Pharma), a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited (CSPC), to transfer the exclusive rights to develop, manufacture and commercialize batoclimab (HBM9161) in Greater China (including mainland China, Hong Kong, Macau and Taiwan) to NBP Pharma. According to the agreement, Harbour BioMed will potentially receive a total of over RMB 1 billion, including an upfront payment of RMB 150 million and other potential milestone payments. In addition, the Company will receive tiered royalties based on annual net sales of batoclimab in Greater China.

Batoclimab is the first novel fully human anti-FcRn monoclonal antibody being developed in Greater China. It blocks FcRn-IgG interactions, accelerating the degradation of autoantibodies and leads to the treatment of pathogenic IgG-mediated autoimmune diseases. As the clinically most advanced FcRn inhibitor being developed in Greater China, batoclimab has the potential to be a breakthrough treatment for a wide spectrum of autoimmune diseases in Greater China. Batoclimab is currently undergoing a number of clinical studies in Greater China including myasthenia gravis (MG), immune thrombocytopenia (ITP), neuromyelitis optical spectrum disorder (NMOSD), Thyroid Eye Disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and pemphigus vulgaris (PV).

Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, said: " Over the past few years, we are delighted to see the excellent clinical efficacy of batoclimab, and are also looking forward to the commercialization of this product. CSPC has a leading position in the commercialization of innovative drug products in China, and we are delighted to enter into this cooperation with CSPC to optimize market potential and advance clinical development, so as to further maximize the value of batoclimab in Greater China. In the future, Harbour BioMed will continue to implement the Company's strategy, optimize resources, cultivate its innovative R&D capabilities, and leverage the value of its core platforms to develop more differentiated therapies for patients around the world."

"We are pleased to have reached this agreement with Harbour BioMed," said Cuilong Zhang, CEO of CSPC. "Batoclimab is a promising innovative drug, and we hope to accelerate its clinical development, manufacturing, registration and commercialization in China, so as to benefit the patients in China better and earlier."

About Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.
 
The Company’s proprietary antibody technology platforms Harbour Mice^® generates fully human monoclonal antibodies in two heavy and two light chains (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE^®) bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice^®, and HBICE^® with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies.  

About CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group Limited (CSPC) is an innovation-driven pharmaceutical group in China with strong research and development, manufacture and commercialization capabilities, committed to developing innovative medicines to fill unmet medical needs. CSPC has developed a strong product portfolio with a number of leading products in the therapeutic areas of nervous system diseases, oncology, anti-infectives and cardiovascular diseases. CSPC NBP Pharmaceutical Co. Ltd. is a wholly-owned subsidiary of CSPC, a company listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 1093) and a constituent stock of the Hang Sang Index.